Advertisement

Topics

Novartis breast cancer drug Kisqali wins EU approval

04:07 EDT 24 Aug 2017 | PharmaTimes

Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.

Original Article: Novartis breast cancer drug Kisqali wins EU approval

NEXT ARTICLE

More From BioPortfolio on "Novartis breast cancer drug Kisqali wins EU approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...